454 related articles for article (PubMed ID: 27553599)
1. Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence.
Rodríguez-Gutiérrez R; Montori VM
Circ Cardiovasc Qual Outcomes; 2016 Sep; 9(5):504-12. PubMed ID: 27553599
[TBL] [Abstract][Full Text] [Related]
2. Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Monami M; Candido R; Pintaudi B; Targher G; Mannucci E;
Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2539-2546. PubMed ID: 34158243
[TBL] [Abstract][Full Text] [Related]
3. Glycemic Targets in Diabetes Care: Emerging Clarity after Accord.
Buse JB
Trans Am Clin Climatol Assoc; 2015; 126():62-76. PubMed ID: 26330660
[TBL] [Abstract][Full Text] [Related]
4. Intensive glycemic control and cardiovascular disease: an update.
Brown A; Reynolds LR; Bruemmer D
Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
Meier M; Hummel M
Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
[TBL] [Abstract][Full Text] [Related]
6. Glucose lowering and cardiovascular disease: what do we know and what should we do?
Cheng AY; Leiter LA
Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S25-31. PubMed ID: 20489417
[TBL] [Abstract][Full Text] [Related]
7. Is glycemic control a quinidine-like intervention?
Bloomgarden ZT
J Diabetes; 2014 Sep; 6(5):387-8. PubMed ID: 24842383
[No Abstract] [Full Text] [Related]
8. Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
Menon V; Kumar A; Patel DR; John JS; Wolski KE; McErlean E; Riesmeyer JS; Weerakkody G; Ruotolo G; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
J Am Heart Assoc; 2020 Jan; 9(1):e014328. PubMed ID: 31852422
[TBL] [Abstract][Full Text] [Related]
9. Diabetes. Insights from the extended follow-up of the ACCORD trial.
Zoungas S; Woodward M
Nat Rev Cardiol; 2011 Jun; 8(6):308-10. PubMed ID: 21502962
[TBL] [Abstract][Full Text] [Related]
10. Benefits and harms of intensive glycemic control in patients with type 2 diabetes.
Rodriguez-Gutierrez R; Gonzalez-Gonzalez JG; Zuñiga-Hernandez JA; McCoy RG
BMJ; 2019 Nov; 367():l5887. PubMed ID: 31690574
[TBL] [Abstract][Full Text] [Related]
11. Intensive glucose control and cardiovascular outcomes in type 2 diabetes.
Macisaac RJ; Jerums G
Heart Lung Circ; 2011 Oct; 20(10):647-54. PubMed ID: 20807681
[TBL] [Abstract][Full Text] [Related]
12. Metabolic memory: Evolving concepts.
Misra A; Bloomgarden Z
J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
[TBL] [Abstract][Full Text] [Related]
13. Diabetes and cardiovascular disease: the role of glycemic control.
Cheng AY; Leiter LA
Curr Diab Rep; 2009 Feb; 9(1):65-72. PubMed ID: 19192427
[TBL] [Abstract][Full Text] [Related]
14. [Diabetes is a challenge: A ten year follow up of people with diabetes].
Gudlaugsdottir HL; Sigurdardottir AK
Laeknabladid; 2018 Apr; 104(4):171-176. PubMed ID: 29616657
[TBL] [Abstract][Full Text] [Related]
15. Decrease mortality in type II diabetes mellitus: glycemic and renal function control.
Borghi C; Ventura F
J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e13-e15. PubMed ID: 29538138
[No Abstract] [Full Text] [Related]
16. HbA1c targets in type 2 diabetes: guidelines and evidence.
Drug Ther Bull; 2013 Apr; 51(4):42-5. PubMed ID: 23557845
[TBL] [Abstract][Full Text] [Related]
17. Divergent effects of various diabetes drugs on cardiovascular prognosis.
Bell DS; Patil HR; O'Keefe JH
Rev Cardiovasc Med; 2013; 14(2-4):e107-22. PubMed ID: 24448252
[TBL] [Abstract][Full Text] [Related]
18. Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes.
Mannucci E; Monami M; Ceriello A; Rotella CM
Nutr Metab Cardiovasc Dis; 2017 Apr; 27(4):375-377. PubMed ID: 28242233
[No Abstract] [Full Text] [Related]
19. Hypoglycaemic therapy in type 2 diabetes. Part I. Metformin is the only glucose-lowering drug known to prevent complications of diabetes.
Prescrire Int; 2015 Apr; 24(159):103-6. PubMed ID: 25941708
[TBL] [Abstract][Full Text] [Related]
20. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study.
Cardoso CRL; Leite NC; Moram CBM; Salles GF
Cardiovasc Diabetol; 2018 Feb; 17(1):33. PubMed ID: 29477146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
